CAP-003
Parkinson's Disease Associated with GBA Mutations (PD-GBA)
Key Facts
About Capsida Biotherapeutics
Capsida Biotherapeutics is a private, clinical-stage biotech company pioneering a novel approach to gene therapy through its proprietary AAV capsid engineering platform. Founded in 2019 and based in Thousand Oaks, California, the company is developing targeted, IV-administered therapies designed to deliver genetic cargo specifically to diseased tissues while minimizing off-target effects. With a fully integrated model spanning discovery through GMP manufacturing, Capsida is advancing a pipeline led by programs for STXBP1-DEE and PD-GBA, backed by strategic collaborations with AbbVie, CRISPR Therapeutics, and Lilly. The company is financed by leading venture firms and faces the inherent risks of clinical development, including recent serious adverse events in its lead program.
View full company profile